https://www.selleckchem.com/products/mv1035.html
© 2020 WILEY-VCH Verlag GmbH Co. KGaA, Weinheim.BACKGROUND Ramucirumab plus docetaxel (RAM+DOC) is expected to prolong survival in patients with advanced non-small cell lung cancer (NSCLC); however, the efficacy and safety for older patients remains unknown. The objective of this study was to evaluate the efficacy and safety of RAM+DOC in patients 75 years and older. METHODS We retrospectively reviewed consecutive patients with advanced NSCLC who had received RAM+DOC treatment at three institutions. We compared the efficacy and saf
Gefällt mir
Kommentar
Teilen
